# Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy

> **NCT00611455** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 265 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** ofatumumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00611455
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01-01
- **Primary completion:** 2009-06-08
- **Final completion:** 2013-07-15
- **Target enrollment:** 265 (ACTUAL)
- **Why stopped:** Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical development of autoimmune indications on the subcutaneous delivery.
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611455, "Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00611455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*